1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Devyser Diagnostics AB

Devyser Diagnostics AB

50.00
SEK
-0.50
(-0.99%)
1.16EPS
73.71P/E
1.45BMarket Cap
Nov 03Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
4.21
5.62
6.02
8.32
7.95
10.46
13.23
15.1
15.68
Basic EPS, GAAP
- -
0.05
0.61
-1
-1.85
-2.89
-3.31
-3.75
-0.51
1.16
Free Cash Flow per Basic Share
- -
0.08
0.47
-0.26
-2.25
-4.16
-6.29
-7.78
-3.74
-1.3
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.57
2.62
3.24
2.69
27.43
26.76
23.65
21.08
21.27
22.56
Tangible Book Value per Share
1.47
1.32
1.45
1.43
26.23
24.29
20.2
14.91
11.63
11.23
Basic Weighted Avg Shares
11
11
11
11
11
16
16
16
17
17
Sales/Revenue/Turnover
- -
48
64
66
93
127
169
217
251
261
Operating Margin (%)
- -
-2.49
13.82
-16.69
-25.1
-43.29
-33.25
-28.86
4.59
10.14
Depreciation Expense
- -
3
5
13
6
9
13
28
27
29
Net Income, GAAP
- -
1
7
-11
-21
-46
-54
-61
-8
19
Effective Tax Rate (%)
- -
- -
27.22
- -
- -
- -
- -
- -
- -
19.17
Profit Margin (%)
- -
1.08
10.9
-16.61
-22.17
-36.33
-31.66
-28.35
-3.35
7.42
Working Capital
20
18
17
12
383
361
279
180
133
135
LT Debt
6
8
20
15
10
16
57
45
38
33
Total Equity
29
30
37
31
417
431
385
349
354
381
Return on Invested Capital (%)
- -
- -
14.48
- -
- -
- -
- -
- -
- -
5.27
Return on Capital (%)
- -
- -
15.08
- -
- -
- -
- -
- -
- -
6.19
Return on Common Equity (%)
- -
1.75
20.93
-32.19
-9.26
-10.85
-13.13
-16.76
-2.39
5.45

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
14
14
13
LT Borrowings
- -
- -
- -
LT Finance Leases
38
35
32
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
1,902
1,261
1,449

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
204
199
206
Cash, Cash Equivalents & STI
78
75
81
Accounts Receivable, Net
57
58
60
Inventories
37
42
44
Total Current Liabilities
71
69
71
Payables & Accruals
- -
- -
- -
ST Debt
14
14
13
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
247.8%
1.52%
Free Cash Flow
- -
199.3%
-51.41%
Net Income, GAAP
- -
31.36%
-86.34%
Sales/Revenue/Turnover
- -
31.02%
15.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
51
53
49
64
217
2025
55
67
- -
72
251
2026
62
60
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.75
-1.4
-1.41
-0.19
-3.75
2025
-1.24
0.08
- -
0.82
-0.51
2026
0.17
0.1
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jan Thomas Wahlström
Full Time Employees
116
Sector
Health technology
Industry
Medical specialties
Address
Bränningevägen 12 Årsta AB Sweden 120 54
IPO Date
Dec 10, 2021
Website
devyser.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Devyser Diagnostics AB (publ) (DVYSR.ST) develops, manufactures and sells diagnostic kits and software solutions for advanced DNA testing in hereditary diseases, oncology and post-transplantation monitoring. The company offers next-generation sequencing (NGS)-based assays including Devyser Genomic Blood Typing for comprehensive genetic blood group analysis covering red blood cell, human platelet antigen and human neutrophil antigen systems; Devyser HLA Loss for post-transplant research; Devyser CFTR for complete sequencing of the CFTR gene in cystic fibrosis; tests for thalassemia, BRCA in breast, colorectal and ovarian cancer; prenatal aneuploidy and non-invasive fetal RhD screening; cardiovascular panels for familial hypercholesterolemia; hematology panels for blood conditions; and chimerism and cell-free DNA monitoring for transplant patients such as One Lambda Devyser Chimerism and Devyser Accept cfDNA; alongside Amplicon Suite and Advyser software for data analysis. Products target routine diagnostic laboratories serving personalized cancer therapies, genetic disease diagnosis and transplant follow-up, with sales through direct channels and distributors to over 65 countries across Europe, the Middle East, Africa, Asia-Pacific, North and South America. Devyser Diagnostics AB (publ), founded in 2004, is headquartered in Stockholm, Sweden, and operates a CLIA-certified laboratory in Atlanta, Georgia, with in-house sales offices in Europe and the US. Recent developments include the global launch of Devyser Genomic Blood Typing and Devyser HLA Loss in June 2025; IVDR certification for Devyser CFTR in November 2025 and earlier products like kidney transplant monitoring assays; a major SEK 16.8 million tender win in Italy in February 2025 for CFTR, BRCA and thalassemia NGS tests representing 30% growth over prior contract; partnership with Quest Diagnostics in Q3 2025 to add fetal RhD test to its US portfolio; expanded collaboration with Thermo Fisher Scientific for FDA approval pursuit of kidney transplant cfDNA test; CMS pricing approval for PrenatalDetect RhD in the US; and appointment of Jan Wahlström as CEO in August 2025.